Treatment Benefit and Daily Drug Costs Associated with Treating Parkinson's Disease in a Parkinson's Disease Clinic

CNS Drugs

Volumn 18, Issue 2, 2004, Pages 105-111

  Müller, Thomas ^a   Voß, Birgit ^b   Hellwig, Kerstin ^a,b   Stein, Franz Josef ^b   Schulte, Thorsten ^a,b   Przuntek, Horst ^a,b  

^a ST JOSEF HOSPITAL   (Germany)

^b Department of Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; BUDIPINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADULT; AGED; ARTICLE; CALCULATION; CAREGIVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; EVALUATION; EXPERIENCE; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; OBSERVATION; OUTPATIENT DEPARTMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; TITRIMETRY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALS, SPECIAL; HUMANS; INPATIENTS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PROSPECTIVE STUDIES; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX;

EID: 18544400619     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418020-00004     Document Type: Article

References (29)

1. Ben Shlomo Y. The epidemiology of Parkinson's disease. Baillieres Clin Neurol 1997; 6 (1): 55-68
2. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000; 23 (10 Suppl.): S2-7
3. Clarke CE. Medical management of Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 72 Suppl. 1: I22-7
4. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16 (1): 59-69
5. Shimbo T, Hira K, Takemura M, et al. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. Pharmacoeconomics 2001; 19 (8): 875-86
6. Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998; 14 (5): 541-57
7. Montgomery Jr EB, Lieberman A, Singh G, et al. Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. PROPATH Advisory Board. Am J Med 1994; 97 (5): 429-35
8. Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson's disease. Pharmacoeconomics 2001; 19 (7): 729-52
9. Stebbins GT, Goetz CG, Lang AE, et al. Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. Mov Disord 1999; 14 (4): 585-9
10. Martinez-Martin P, Fontan C, Frades PB, et al. Parkinson's disease: quantification of disability based on the Unified Parkinson's Disease Rating Scale. Neurologia 2000; 15 (9): 382-7
11. Nutt JG, Lea ES, Van Houten L, et al. Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice. Mov Disord 2000; 15 (5): 843-9
12. Soliveri P, Brown RG, Jahanshahi M, et al. Effect of practice on performance of a skilled motor task in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55 (6): 454-60
13. Müller T, Schafer S, Kuhn W, et al. Correlation between tapping and inserting of pegs in Parkinson's disease. Can J Neurol Sci 2000; 27 (4): 311-5
14. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55 (3): 181-4
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17 (5): 427-42
16. Fahn S, Elton R, and Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, et al., editors. Recent developments in Parkinson's disease II. New York: Macmillan, 1987: 153-63
17. Müller T, Kuhn W, Schulte T, et al. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Neurosci Lett 2003; 339 (1): 25-8
18. Müller T, Benz S. Quantification of the dopaminergic response in Parkinson's disease. Parkinsonism Relat Disord 2002; 8 (1): 181-6
19. Müller T, Benz S, Przuntek H. Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. Can J Neurol Sci 2002; 29 (1): 73-7
20. Braak H, Braak E, Yilmazer D, et al. New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J Neural Transm Suppl 1996; 48: 1-6
21. Rote Liste. Aulendorf: Editio Cantor Verlag, 2002
22. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344 (10): 710-9
23. Hely MA, Morris JG, Traficante R, et al. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999; 67 (3): 300-7
24. Przuntek H, Welzel D, Gerlach M, et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects: long-term results of the PRADO study. J Neural Transm Gen Sect 1996; 103 (6): 699-715
25. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med 2000; 342 (20): 1484-91
26. Przuntek H, Bittkau S, Bliesath H, et al. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 2002; 59 (5): 803-6
27. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology 1998; 50 (5 Suppl. 5): S46-53
28. Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002; 105 (4): 245-55
29. Müller T. Dopaminergic substitution in Parkinson's disease. Expert Opin Pharmacother 2002; 3 (10): 1393-403